Prevention
There is no vaccine for SARS, although immunologist Anthony Fauci mentioned that the CDC developed one and placed it in the US national stockpile. That vaccine, however, is a prototype and not field-ready as of March 2020. Clinical isolation and quarantine remain the most effective means to prevent the spread of SARS. Other preventive measures include:

Hand-washing with soap and water, or use of alcohol-based hand sanitizer
Disinfection of surfaces of fomites to remove viruses
Avoiding contact with bodily fluids
Washing the personal items of someone with SARS in hot, soapy water (eating utensils, dishes, bedding, etc.) Avoiding travel to affected areas
Wearing masks and gloves
Keeping people with symptoms home from school
Simple hygiene measures
Isolating oneself as much as possible to minimize the chances of transmission of the virusMany public health interventions were made to try to control the spread of the disease, which is mainly spread through respiratory droplets in the air, either inhaled or deposited on surfaces and subsequently transferred to a bodys mucous membranes. These interventions included earlier detection of the disease; isolation of people who are infected; droplet and contact precautions; and the use of personal protective equipment (PPE), including masks and isolation gowns. A 2017 meta-analysis found that for medical professionals wearing N-95 masks could reduce the chances of getting sick up to 80% compared to no mask. A screening process was also put in place at airports to monitor air travel to and from affected countries.SARS-CoV is most infectious in severely ill patients, which usually occurs during the second week of illness.
Research
In July 2004, Actelion started a clinical trial of miglustat to treat Tay–Sachs disease, particularly late-onset Tay–Sachs with an estimated enrollment of 10 subjects; the trial ended August 2007.In November 2007, Actelion initiated a clinical trial with miglustat in people with cystic fibrosis (CF) who have the ΔF508 in both copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene; the study ended in March 2008. The cystic fibrosis trial showed no effect. See also
Migalastat, a drug for the treatment of Fabry disease, with a similar structure
Miglitol, an oral antidiabetic drug with a similar structure

References
External links
"Miglustat". Drug Information Portal. U.S. National Library of Medicine.